Upcoming Poster Presentation Announcement
Compass Therapeutics, Inc. (NASDAQ: CMPX), a pioneering clinical-stage biopharmaceutical company specializing in oncology, has announced an exciting opportunity to showcase its research at the upcoming 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting. This event is scheduled to take place from November 8–10, 2024, in a prominent venue in Houston, Texas.
Details of the Presentation
The company is set to present an abstract during this significant meeting, reflecting its commitment to advancing cancer treatment through innovative antibody-based therapeutics. The poster is titled "Pharmacodynamic and Response Biomarkers in the Monotherapy Arm of a Phase 1 Trial of CTX-471, a Novel Anti-CD137 Agonist Antibody," and promises to shed light on critical discoveries in the realm of immunotherapy.
Key Participants in the Presentation
A distinguished group of researchers and professionals will be involved in the poster presentation. The authors include Kris Sachsenmeier, Niharika Mettu, Martin Gutierrez, Jeffery Edenfield, Seth Rosen, Minal Barve, Karin Herrera, Natalie Warholic, Diana Albu, Alberto Visintin, Thomas Schuetz, and Tanner Johanns. Their collaboration embodies the diverse expertise necessary for comprehensive cancer research.
Abstract and Presentation Schedule
The abstract number assigned to this presentation is 679. Attendees are invited to engage with the research on Friday, November 8, 2024, from 9:00 AM to 7:00 PM CDT at Exhibit Halls AB. This extended timeframe allows for in-depth discussions and insights into the findings presented.
About Compass Therapeutics
Founded in 2014, Compass Therapeutics is deeply committed to exploring the intersections between angiogenesis and the immune response in cancer. The company’s innovative strategies focus on targeting multiple biological pathways essential for an effective anti-tumor response. This includes not only angiogenesis-related therapies but also strengthening the immune system’s ability to combat tumor growth by utilizing proprietary antibodies.
Future Directions and Innovations
As a forward-thinking organization, Compass Therapeutics is dedicated to driving its product candidates through rigorous clinical development. Their pipeline includes groundbreaking therapeutic options designed to function both on their own and in combination with existing treatment modalities. This strategy is driven by a commitment to maximizing patient outcomes and enhancing treatment efficacy.
Investor and Media Inquiries
For further engagement or inquiries, Compass Therapeutics maintains a clear line of communication for investor relations through their email at ir@compasstherapeutics.com. Media inquiries can be directed to Anna Gifford, the Senior Manager of Communications, available at 617-500-8099 or via email at media@compasstherapeutics.com.
Frequently Asked Questions
What is the significance of the SITC Annual Meeting?
The SITC Annual Meeting is a pivotal event where researchers and clinicians discuss advancements in cancer immunotherapy, showcasing the latest findings and fostering collaboration.
What are the main focuses of Compass Therapeutics?
Compass Therapeutics primarily focuses on developing antibody-based therapeutics that target critical pathways involved in cancer progression and immune evasion.
Who authored the poster presentation for Compass Therapeutics?
A talented group of researchers, including experts like Kris Sachsenmeier and Niharika Mettu, contributed to the poster presentation highlighting their collaborative efforts in the field.
When and where will the presentation take place?
The poster presentation is scheduled for November 8, 2024, at Exhibit Halls AB as part of the SITC Annual Meeting.
How does Compass Therapeutics approach drug development?
Compass takes a multifaceted approach to drug development, working on both standalone therapies and combinations that leverage supportive clinical and nonclinical data.
